Slides
Page 1
AGM Presentation October 2026
Page 2
2 Our Technology Mining and Manufacturing Sample Preparation Technology Chemical Analysis Raw Samples Prepared Samples Minerals: Iron ore Gold Nickel Copper Aluminium Bauxite Manganese Uranium Lithium Mineral sands Commercial labs Materials: Cement Metals Glass Ceramics Research Education Analysis Techniques: XRF ICP Fire Assay Photon Assay
Page 3
3 Our Technology Sample Analysis Technologies Chemistry Methods Covered: Thermogravimetric Analysis CS/ONH Elemental Analysis pH Measurement
Page 4
44 Orbis Laboratory Crushers For mineral analysis labs (XRF, ICP, Fire Assay, Photon Assay) 55x Sample Size Reduction Crushes 110mm drill core samples down to 2mm in a single pass. Industry leading sample crushing times Automated Sample Splitting Creates a reference sample for elemental analysis. Eliminates human errors from manual splitting processes Robust Design Designed to withstand harsh mining conditions and operate around the clock Operator Safety Reduced operator exposure to manual handling risks with automated sample loaders
Page 5
5 Lab Products Platinum Labware X-Ray Flux Fusion Machines Recycling service of turning used platinum products into new items Sample Preparation Products For mineral and material analysis labs (XRF, ICP)
Page 6
XRTGA 1100 Thermogravimetric Analyser 6 Lab Products Analytical Instruments Used for thermal analysis of moisture, volatiles, ash, fixed carbon or loss on ignition Used in existing mining / construction material industries and new markets such as production quality control of food, plastics and agricultural products Provides complementary data for the XRF analysis process in materials such as iron ore and cement TGA Labs of the Future
Page 7
CS/ONH Elemental Analysis Carbon, Sulphur, Oxygen, Nitrogen, Hydrogen 7 Lab Products Analytical Instruments Application examples: • Iron, Steel, Cobalt, Nickel, Ferroalloys, Aluminium, Magnesium: production quality control • High strength alloys: quality control for uses in industries such as space, aviation, military, nuclear energy and biomedical • Copper production: copper grading process • Magnetic materials: rare earth magnet quality control • Welding: prevention of diffusible hydrogen induced weld failure • Additive manufacturing: metal powder quality control • More: minerals, glass, ceramics, cement, case hardening
Page 8
8 Strong demand from mining and industrial customers International sales growth in numerous developing markets, in particular Asia Continued strong growth in Orbis crusher sales Acquired CGA Elemental Analysis Instrument business on 23 April 2026 for upfront consideration of USD $4m from Bruker AXS SE New international offices opened in India and USA Positioned Capital Equipment division for significant growth in FY27 through Orbis, xrTGA, new CGA product line and new product releases FY26 Highlights
Page 9
9 Revenue up 8% to $64.4m vs FY25 Adjusted NPBT* up 10% to $16.1m vs FY25 NPAT up 1% to $10.5m vs FY25 after expensing acquisition and new international offices setup/startup costs. Effective tax rate increased to 32% from 29% $11.4m positive operating cashflow 49.3% gross margins vs 48.4% in FY25 Fully franked dividend of 4.5 cents per share Record quarterly adjusted profit before tax* of $4.7m from revenue of $17.2m during June Q4, driven by strong consumable and Orbis crusher sales, and growth in international sales FY26 Financial Highlights 5,130 6,094 7,686 8,885 10,383 10,488 FY21 FY22 FY23 FY24 FY25 FY26 Net Profit After Tax ($'000) 31,295 40,009 55,261 60,117 59,448 64,400 FY21 FY22 FY23 FY24 FY25 FY26 Revenue ($'000) *Excludes acquisition costs and setup/startup costs for two new international offices, which were $0.57m in Q4 and totalled $0.69m for FY26 4,511 3,154 8,417 8,090 10,141 11,389 FY21 FY22 FY23 FY24 FY25 FY26 Operating Cashflow ($'000) 6,788 8,175 11,107 12,616 14,636 16,063 FY21 FY22 FY23 FY24 FY25 FY26 *Adjusted PBT ($'000)
Page 10
10 ($m) 2026 2025 Change Cash and cash equivalents 9.5 12.2 (23%) Trade and other receivables 9.7 10.3 (5%) Inventories 21.0 18.8 12% Other assets 0.7 0.6 19% Property, plant and equipment 10.9 10.1 8% PPE lease asset 1.3 1.7 (22%) Intangible assets 23.9 17.3 38% Deferred tax asset 1.6 1.8 (13%) Total assets 78.6 72.8 8% Trade and other payables - platinum loan provisions 0.0 0.7 (100%) - other items 7.8 7.1 11% Debt (short-term) 0.2 0.2 0% Debt (long-term) 0.8 0.9 (18%) Current lease liabilities 0.7 0.8 (12%) Non-current lease liabilities 0.7 1.0 (27%) Income tax liability 1.0 0.9 6% Deferred tax liability 1.1 1.0 10% Total liabilities 12.3 12.6 (3%) Total equity 66.3 60.2 10% Net cash position of $8.5m CGA Acquisition was funded 100% in cash and increased: Inventories by $1.0m Intangible assets by $6.2m Trade and other payables – other items (acquisition earnout liability) by $1.4m Balance Sheet
Page 11
11 ($m) 2026 2025 Net cash inflow from operating activities 11.4 10.1 Net cash outflow from investing activities (8.1) (2.2) Net cash outflow from financing activities (6.0) (7.7) Cash at start of period 12.2 12.0 Net increase / (decrease) in cash (2.7) 0.2 Cash at end of period 9.5 12.2 Highlights: Strong operating cashflow conversion above NPAT Investing activities: $5.6m for CGA acquisition Financing activities: $5.0m cash paid out for FY25 dividend (FY24 dividend: $4.1m) Cash Flow Statements
Page 12
12 September 2026 Quarterly Report Quarter results for period ended 30 September Unaudited September 2026 Quarter September 2025 Quarter Change % Revenue $21.1m $15.3m 38% Profit Before Tax $4.4m $3.4m 30% Consumables: Sales $5.6m for Q1 27 (Q1 26: $4.4m) The strong level of sales activity was driven by customers both in Australia and internationally Conditions for consumable sales have remained positive for the first part of October Capital Equipment: Sales $5.9m for Q1 27 (Q1 26: $5.0m) Orbis increased revenue by 66% to $2.4m, which was driven by commercial labs and the gold sector. Orbis launched the OM25 crusher and Standalone RSD/LSD. We expect Orbis to have a very strong December quarter, with our already large order book expected to grow significantly Integration of the CGA product line is progressing well, with production of instruments expected to start in Perth during December Q2. A large backlog of CGA instrument orders is building, which is expected to start converting into sales during the next quarter Precious Metals: Sales $9.6m for Q1 27 (Q1 26: $5.9m) With the platinum price reducing, new metal product sales have increased back to normalised levels. Recycling of platinum products are also at positive levels Sales included a one-off $2.05m precious metals sale, with a margin of $0.1m, related to the closure of a platinum inventory lease. The off-balance-sheet lease was no longer required, as the division has been building its own platinum inventory position over the last decade. Rather than returning the metal, it was sold on behalf of the Lessor at their request The September 2026 quarter was a very strong period, with all divisions contributing to the result. The September quarter has historically been XRF’s least profitable period each financial year, with this quarter’s growth driven by strong momentum in consumable and capital equipment sales. Outlook: We expect the December 2026 quarter to be another strong trading period, with new revenue coming online from CGA instruments and significant growth from Orbis. During this period our key focus areas are commencing CGA instrument production in Perth, new product developments and international sales growth. Orbis Standalone RSD/LSD Orbis OM25 Crusher
Page 13
13 Contact Information Tel: (08) 9244 0600 86 Guthrie Street Osborne Park WA 6017 Vance Stazzonelli – CEO vance@xrfscientific.com
Page 14
No responsibility for contents of Investor Presentation •To the maximum extent permitted by law, XRF Scientific Limited and representatives: •make no representation, warranty or undertaking, express or implied, as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient; •accept no responsibility or liability as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient; and •accept no responsibility for any errors or omissions from this Investor Presentation whether arising out of negligence or otherwise. Accuracy of projections and forecasts •This Investor Presentation includes certain statements, opinions, estimates, projections and forward-looking statements with respect to the expected future performance of XRF Scientific Limited. These statements are based on, and are made subject to, certain assumptions which may not prove to be correct or appropriate. Actual results may be materially affected by changes in economic and other circumstances which may be beyond the control of XRF Scientific Limited. Except to the extent implied by law, no representations or warranties are made by XRF Scientific Limited, its advisers or representatives as to the validity, certainty or completeness of any of the assumptions or the accuracy or completeness of the forward-looking statements or that any such statement should or will be achieved. The forward-looking statements should not be relied on as an indication of future value or for any other purpose. No offer to sell or invitation to buy •This Investor Presentation does not, and should not be considered to, constitute or form part of any offer to sell, or solicitation of an offer to buy, any shares in XRF Scientific Limited, and no part of this Investor Presentation forms the basis of any contract or commitment whatsoever with any person. This Investor Presentation does not constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is not permitted under applicable law. Distribution of this Investor Presentation in or from certain jurisdictions may be restricted or prohibited by law. Recipients must inform themselves of and comply with all restrictions or prohibitions in such jurisdictions. Neither XRF Scientific Limited, its advisers or representatives accept any liability to any person in relation to the distribution or possession of this Investor Presentation from or in any jurisdiction. 14 Disclaimer